Therapeutic Insights
Filter News
Found 299 articles
-
ProMIS Neurosciences congratulates Biogen on FDA accelerated approval of aducanumab for Alzheimer’s disease
6/8/2021
ProMIS Neurosciences, Inc. today congratulates Biogen on the recent FDA approval of its monoclonal antibody therapeutic, aducanumab.
-
The U.S. Food and Drug Administration granted approval of Biogen’s aducanumab for the treatment of Alzheimer’s disease.
-
Alzheimer’s patients and their families wait with hope that this will mean some offer of treatment, while physicians that treat Alzheimer’s patients are mulling the implications of the drug, often with hesitancy and skepticism.
-
Oligomerix to Participate in Upcoming Life Sciences Conferences
6/3/2021
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, announced that President and CEO James Moe, Ph.D., MBA will be participating in upcoming life sciences conferences in June.
-
Cortexyme Presents Updated Baseline Data from Complete Set of Participants Enrolled in Pivotal GAIN Trial at ASCP 2021 Annual Meeting
6/1/2021
Cortexyme Presents Updated Baseline Data from Complete Set of Participants Enrolled in Pivotal GAIN Trial at ASCP 2021 Annual Meeting Baseline demographic and biomarker data reinforce appropriate patient population enrolled ahead of top-line data expected in fourth quarter 2021
-
George C. McFarland, MSW Joins Evon Medics, LLC as Advisor
6/1/2021
Small business, Evon Medics, LLC today announced that community engagement and social work consultant, Mr. George C. McFarland has joined the advisory board of the company in a formal advisory role.
-
Annovis Bio's ANVS401 Improves Speed and Accuracy in Alzheimer's and in Parkinson's Patients
6/1/2021
AD and PD patients both respond with a statistically significant increase in correctly coded fields after 25 days of treatment with ANVS401.
-
FDA: BrainSee Novel Software Is Breakthrough for Noninvasive Detection and Monitoring of Alzheimer's Disease at the Early Stage of Mild Cognitive Impairment
5/28/2021
Such early detection or rule-out of Alzheimer's disease non-invasively and affordably is nonexistent in the clinical market today.
-
Preliminary data from Annovis Bio’s Phase II study of ANVS401 shows significant cognitive improvements in Alzheimer’s patients after only one month of treatment.
-
The team has taken a fundamentally new approach to Alzheimer’s, and it centers around the hypothesis that there are multiple drivers causing the disease.
-
Annovis Bio Announces Positive Phase 2 Data - ANVS401 Improves Cognition in Alzheimer's Disease - Patients' Cognition Improved 3.3 Points on ADAS-Cog11
5/21/2021
The 11-part test is one of the most frequently used tests to measure impaired cognition in clinical trials for AD.
-
Annovis Bio to Participate in Alzheimer Disease Panel Presented by Maxim Group LLC and Hosted by M-Vest on May 26th, 2021
5/20/2021
The panel discussion, led by Dr. Jason McCarthy, Maxim's Senior Managing Director of Biotechnology Equity Research, and including other voices in the healthcare industry, will cover exciting topics in AD drug development.
-
A new study from Johns Hopkins University Bloomberg School of Public Health suggests the development of dementia is associated with abnormal levels of plasma proteins, and these proteins may be predictive of dementia up to five years before a patient receives a diagnosis.
-
Annovis Bio Files for FDA Orphan Drug Designation for ANVS401 for the Treatment of Alzheimer's Disease in Persons with Down Syndrome
5/18/2021
DS occurs in about 1 in 700 newborns and approximately 200,000 people in the U.S. have the condition.
-
Trial First to Show Improvements in Alzheimer's Patients
5/13/2021
Pharmaceutical trials for Alzheimer's have failed repeatedly, but a new study, using a fundamentally different approach, has provided the first success: using precision medicine to identify and target the drivers of Alzheimer's or pre-Alzheimer's in each patient,
-
Leen Kawas, president and CEO of Athira Pharma, comes from a long line of successful, trailblazing women who place an emphasis on inspiring the next generation, and she is driven to defeat neurodegenerative disease, which has stolen two of those women from her.
-
With Biogen’s potential treatment for Alzheimer’s, aducanumab, coming in weeks before a U.S. FDA decision, ICER wrote a punishing report slamming the drug for insufficient efficacy and recommending a low price point if approved.
-
Oral Nanoparticle-Encapsulated Bryostatin-1 Found Effective for Treating Cognitive Deficits in an Alzheimer’s disease Mouse Model
5/4/2021
Aphios Corporation announced today its research demonstrated that orally-administered nanoparticle-encapsulated Bryostatin-1 activates α-secretase and PKC isoforms in vitro, and facilitates acquisition and retention of spatial learning in vivo in an Alzheimer's disease mouse model.
-
Cortexyme to Present at the BofA Securities 2021 Healthcare Conference on May 11, 2021
5/4/2021
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, today announced Chris Lowe, the company’s chief operating officer and chief financial officer, will participate in a fireside chat at the BofA Securities 2021 Healthcare Conference, a virtual event
-
There are seven stages of Alzheimer’s disease, and understanding each stage is a useful aid in setting your expectations whether you might have the disease or you’re caring for someone with the illness.